Hybrigenics extends its partnership with Servier

27 January 2015

French biopharma company Hybrigenics (Euronext Paris: ALHYG) says it has extended its partnership with France’s leading independent pharma company Servier to discover new drugs which inhibit Ubiquitin-Specific Proteases (USPs).

This partnership was initiated in October 2011. A first research milestone has been reached one year ago in the field of oncology. The overall work and achievement have already given rise to total cumulated revenues of close to 4.3 million euros ($4.8 million) for Hybrigenics.

Hybrigenics says the results obtained as of today reinforce its confidence in one USP as a target of interest against certain cancers and justify the research extension for one year, with an additional amount of 0.92 million euros committed to Hybrigenics.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK